A Phase 2 interventional study of Doxecitine and Doxribtimine in Thymidine Kinase 2 (TK2 ) Deficiency and Mitochondrial Myopathies, sponsored by Cristina Domínguez González. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Cristina Domínguez González · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this clinical trial is to evaluate the efficacy and safety of Doxecitin and Doxribtimine (dC+dT) in adult participants with thymidine kinase 2 (TK2) deficiency attended in the Neuromuscular Unit of '12 de Octubre' Hospital.
The main questions it aims to answer are:
Researchers will evaluate the effectiveness of the treatment doxecitin and doxribthymine in adult participants with TK2 deficiency. In addition, the mitochondrial DNA levels before and after treatment (extracted from the muscle and from uroepithelial cells) of these participants will be also studied.
This is an Open Label, single-arm, single-center clinical study to evaluate the efficacy and safety of dT+dC in adults with TK2 deficiency (TK2d). TK2 deficiency is one of several mitochondrial autosomal recessive disorders that are collectively referred to as mitochondrial DNA depletion and multiple deletions syndromes (MDDS), in fact, TK2d is an ultra-rare disease, presenting as progressive proximal muscle weakness in all patients; however, clinical presentations are heterogeneous in nature and manifest with variable levels of severity and functional impairment across patients.
The study seeks to enroll patients under follow-up in the Neuromuscular Unit of '12 de Octubre' Hospital. All participants will be required to attend a screening visit at which their eligibility for the study will be determined. After signing the informed consent and verifying that they met all inclusion and exclusion criteria, participants will receive a daily dose of dT+dC in 3 equal divided doses administered orally at an approximate interval of 6 (±2) hours. dT+dC is to be initially dosed (commencing on Day 1) at 130 mg/kg/day of each nucleoside (130 mg/kg/day dC and 130 mg/kg/day dT), divided into 3 equal daily doses of approximately 43 mg/kg/dose. If the tolerability profile is acceptable after 2 weeks (approximately Day 15), the dose is to be increased to 260 mg/kg/day of each nucleoside (approximately 86 mg/kg/dose three-times daily, (TID). If the tolerability profile remains acceptable after an additional 2 weeks of dosing (approximately Day 29) the dose is to be further increased to 400 mg/kg/day (approximately 133 mg/kg/dose TID). The maximum dose is 400 mg/kg/day. The tolerability profile of the treatment will be evaluated based on whether the patient has diarrhea.
The total number of participants for the safety and efficacy analysis will be 10 to 15 participants with progressive myopathy with respiratory involvement.
The estimated duration of the study for individual participants will be 24 months. Although, based on previous experience in treating these patients, the investigators expect to see results within the first 6 to 12 months of treatment.
It is hypothesized that dT+dC oral administration is safe, well tolerated and clinically beneficial in adults with TK2 deficiency.
46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.
This study's planned enrollment of 15 is below the median of 24 across 31 interventional studies indexed under Mitochondrial Myopathies.
Browse Mitochondrial Myopathies studies →Cristina Domínguez González is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject should have evidence of a moderate to severe disease, with motor and or respiratory involvement, shown by one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an open label study with all participants in a single arm. Study participants will take doxecitine and doxribtimine up to a maximum of 800 mg/kg/day (400 mg/kg/day doxecitine and 400 mg/kg/day doxiribtimine).
Drug: Doxecitine and Doxribtimine
A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.
Efficacy - Motor Function Assessments: Neurological Exam using Medical Research Council (MRC Scale) Scale for Muscle Strength
Motor Function will be measured using the MRC scale. The scale provides a measure of Muscle Strength across a range from 0 (No visible muscle contraction) to 5 (Full strength)
Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
Efficacy - Motor Function Assessments: 6-minute walk test
Motor Function will be measured using the 6-minute walk test (6MWT). Distance walked in meters over 6 minutes will be measured
Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
Efficacy - Motor Function Assessments: North Star Ambulatory Assessment (NSAA)
Motor function will be assessed using the NSAA scale. The NSAA is a 17-item scale that grades performance of various functional activities on a scale graded 0 (unable to complete the activity), 1 (completes the activity independently but with modifications), and 2 (completes the activity without modifications)
Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
Efficacy - Motor Function Assessments: 100 meter-time velocity test
Time to run 100 meters measured in seconds (sec)
Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
Efficacy - Motor Function Assessments: Fatigue Scale test
Motor function will be assessed Fatigue Scale test. The FACIT-Fatigue is a 13-item patient-reported outcome measure (range from 0 to 52: 0 = very much fatigued, 52 = not at all fatigued) assessing fatigue over the previous week
Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
Efficacy - Respiratory Assessments measured by spirometry
* Sitting Forced Vital Capacity (Sitting FVC) measure in percentage (%) * Drop in FVC lying down measured in percentage (%) * Maximal Inspiratory Pressure (MIP) measure in percentage: Evaluation of the strength of respiratory muscles is performed with measurements of MIP expressed in percentage (%) * Maximal Inspiratory Pressure (MEP) measure in percentage: Evaluation of the strength of respiratory muscles is performed with measurements of MEP expressed in percentage (%)
Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
Efficacy - Respiratory Assessments: Use of ventilatory support (Use and Type )
Use and Type of mechanical ventilation (MV) \[bilevel positive airway pressure (BiPAP) and/or continuous positive airway pressure (CPAP)\] per subject will be assessed
Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
Efficacy - Respiratory Assessments: Time of use of ventilatory support
Total of hours of use of mechanical ventilation (MV) per subject will be assessed
Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
Serum Biomarkers: lactate levels
Number of participants with normal vs abnormal lactate levels measured in mmol/l
Time frame: Up to 24 months
Serum Biomarkers: Growth/differentiation factor-15 (GDF15 )
Number of participants with normal vs abnormal Growth/differentiation factor-15 (GDF15) levels measured in mmol/l compared to normal ranges
Time frame: Up to 24 months
Safety as adverse events (AEs)
Number of participants who experience adverse events (AEs)
Time frame: Up to 24 months
Safety as serious adverse events (SAEs)adverse events
Number of participants who experience serious adverse events (SAEs)
Time frame: Up to 24 months
Changes in the mtDNA levels before and after treatment
To assess change in mitochondrial DNA (mtDNA) levels, a muscle biopsy with a needle will be performed before entering the study and 6 months after the start of treatment
Time frame: 6 month
Changes in the peak oxygen consumption (VO2 max) test
A progressive exercise test will be undertaken at screening to assess peak oxygen consumption (VO2 max) using an electronically braked recumbent cycle ergometer.
Time frame: 6 month
Plan to share: No
Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cristina Domínguez González